Dr. Stephen Bloch

• 
  www.marinuspharma.com/board.html - [Cached Version]
  Published on: 10/9/2009    Last Visited: 10/9/2009  

  Stephen Bloch, M.D
  ...
  Stephen Bloch, M.D. Chairman Stephen Bloch joined Canaan Partners in June 2002, initially as a Ewing Marion Kauffman Fellow. His investment targets include biopharmaceuticals (therapeutics and diagnostics), medical devices and healthcare infrastructure. Dr. Bloch currently serves on the Board of Directors for Advanced Biohealing, Amicus Therapeutics, Marinus Pharmaceuticals, OmniSonics Medical Technologies and Viacor.
  
  Prior to joining Canaan, Dr. Bloch was a medical entrepreneur and practicing physician. He founded and was CEO of Radiology Management Sciences, a risk manager of diagnostic imaging services for health plans and provider networks. As medical director, he helped start Omnisonics Medical Technologies which is developing breakthrough products using acoustic energy for the treatment of vascular occlusive diseases. Additionally, he co-founded TeleRad, a teleradiology services company, and was an initial investor in OpenAir.com, an enterprise software company for professional services firms. Dr. Bloch started his business career as a strategic consultant with Arthur D. Little focused on pharmaceuticals and medical devices.
  ...
  Dr. Bloch received his medical training as a radiologist at The Massachusetts General Hospital/Harvard Medical School and in internal medicine at The Lenox Hill Hospital/Cornell Medical School. He received his medical degree from the University of Rochester. He also received a M.A. in history of science and public policy from Harvard University and an A.B. degree in history from Dartmouth College.
  
  Dr. Bloch became Chairman of the Marinus Pharmaceuticals board in October 2007.

• 
  www.canaan.com/home/news/archives/20080805-marinus-phar - [Cached Version]
  Published on: 8/5/2008    Last Visited: 10/21/2008  

  "We are pleased that John is taking the helm at Marinus, particularly at such a crucial stage of development of the company's lead compound, ganaxolone, a new class of epilepsy treatment," said Stephen Bloch, chair of the board of directors and general partner of Canaan Partners.

• 
  www.marinuspharma.com/nr_krayacich.html - [Cached Version]
  Published on: 8/5/2008    Last Visited: 10/6/2009  

  "We are pleased that John is taking the helm at Marinus, particularly at such a crucial stage of development of the company's lead compound, ganaxolone, a new class of epilepsy treatment," said Stephen Bloch, chair of the board of directors and general partner of Canaan Partners.

• 
  www.podiatry-arena.com/podiatry-forum/showthread.php?t= - [Cached Version]
  Last Visited: 3/9/2009  

  Stephen Bloch, M.D. a principal with Canaan Partners and Chairman of the ABH Board added, "Our investment focus stresses rapid market entry, and we are delighted that this asset purchase will provide Advanced BioHealing with near- term revenues and the commercial infrastructure necessary for the company's additional products in development."
  ...
  "This launch is a significant milestone and points to the strength and commitment of the ABH management and team," said Stephen Bloch, MD, Venture Partner with Canaan Partners and Chairman of the ABH Board of Directors.

• 
  www.journal-topics.com/gv/07/gv070603.1.html - [Cached Version]
  Published on: 6/3/2007    Last Visited: 6/25/2007  

  "Some residents [thought] it wasn't appropriate, wasn't the right location," said Pascal Ibgui, owner of Pascal Pour Elle and Skin Deep Medical Spa along with partner Dr. Stephen Bloch.

• 
  www.marinuspharma.com/senior_management.html - [Cached Version]
  Published on: 10/6/2009    Last Visited: 10/6/2009  

  Stephen Bloch, M.D. - Chairman
  ...
  Stephen Bloch, M.D. Chairman Stephen Bloch joined Canaan Partners in June 2002, initially as a Ewing Marion Kauffman Fellow. His investment targets include biopharmaceuticals (therapeutics and diagnostics), medical devices and healthcare infrastructure. Dr. Bloch currently serves on the Board of Directors for Advanced Biohealing, Amicus Therapeutics, Marinus Pharmaceuticals, OmniSonics Medical Technologies and Viacor.
  
  Prior to joining Canaan, Dr. Bloch was a medical entrepreneur and practicing physician. He founded and was CEO of Radiology Management Sciences, a risk manager of diagnostic imaging services for health plans and provider networks. As medical director, he helped start Omnisonics Medical Technologies which is developing breakthrough products using acoustic energy for the treatment of vascular occlusive diseases. Additionally, he co-founded TeleRad, a teleradiology services company, and was an initial investor in OpenAir.com, an enterprise software company for professional services firms. Dr. Bloch started his business career as a strategic consultant with Arthur D. Little focused on pharmaceuticals and medical devices.
  ...
  Dr. Bloch received his medical training as a radiologist at The Massachusetts General Hospital/Harvard Medical School and in internal medicine at The Lenox Hill Hospital/Cornell Medical School. He received his medical degree from the University of Rochester. He also received a M.A. in history of science and public policy from Harvard University and an A.B. degree in history from Dartmouth College.
  
  Dr. Bloch became Chairman of the Marinus Pharmaceuticals board in October 2007.

• 
  www.biospace.com/news_story.aspx?StoryId=134409 - [Cached Version]
  Published on: 4/10/2009    Last Visited: 4/13/2009  

  "The management team brings proven and distinctive expertise in developing CNS therapies," said Stephen Bloch, M.D., Partner at Canaan Partners and Chairman of Marinus Pharmaceuticals.

• 
  vcexperts.com/vce/community/directory/default.asp?regio - [Cached Version]
  Published on: 1/7/2008    Last Visited: 1/7/2008  

  Stephen Bloch of Kauffman Fellowship in Venture Capital

• 
  sanjose.bizjournals.com/sanjose/stories/2009/07/20/stor - [Cached Version]
  Published on: 7/17/2009    Last Visited: 7/20/2009  

  Nondilutive financing to help get those companies further along or to supplement venture capital is vital to the process, said Dr. Stephen Bloch, general partner in Canaan Partners' health care investment arm and a practicing physician.
  
  The SBIR program is more important for early stage venture capital than later stage venture capital, he added.
  
  "Without grants, venture capital won't play if it costs so much to play early or the costs aren't defrayed in some fashion," he said.

• 
  www.marinuspharma.com/about/ - [Cached Version]
  Published on: 10/20/2006    Last Visited: 11/24/2007  

  Kenneth R. Shaw, Ph.D. - Vice Pres., Research & Development | Vincent Pieribone, Ph.D. - Founding Discovery Officer | Julia Tsai, Ph.D. - Director, Drug Development | Jean Bernardi - Director of Finance, Controller | Harry H. Penner, Jr. - Chairman & Chief Executive Officer | Stephen Bloch, M.D. | Nicola Campbell, Ph.D. | Nicole Vitulo

Page:  1 2 3 4 5